On the basis of the initial characterization of NSG-Pro, we propose that physiological levels of hPRL restore the endocrine environment adequate for ER+ breast cancer biology and drug responsiveness, making NSG-Pro mice more applicable for testing of pharmacological agents against ER+ breast cancer than conventional NSG mice. This evidence concerns the gene ESR1 and breast carcinoma.